Exelixis, Inc. $EXEL Shares Sold by V Square Quantitative Management LLC

V Square Quantitative Management LLC trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 52.6% in the second quarter, Holdings Channel.com reports. The institutional investor owned 741 shares of the biotechnology company’s stock after selling 822 shares during the quarter. V Square Quantitative Management LLC’s holdings in Exelixis were worth $33,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. GAMMA Investing LLC boosted its stake in shares of Exelixis by 4,779.4% in the first quarter. GAMMA Investing LLC now owns 201,472 shares of the biotechnology company’s stock valued at $7,438,000 after purchasing an additional 197,343 shares during the period. Merit Financial Group LLC boosted its stake in shares of Exelixis by 154.8% in the first quarter. Merit Financial Group LLC now owns 33,453 shares of the biotechnology company’s stock valued at $1,235,000 after purchasing an additional 20,325 shares during the period. Sivia Capital Partners LLC boosted its stake in shares of Exelixis by 22.9% in the first quarter. Sivia Capital Partners LLC now owns 11,598 shares of the biotechnology company’s stock valued at $428,000 after purchasing an additional 2,162 shares during the period. UMB Bank n.a. boosted its stake in shares of Exelixis by 113.0% in the first quarter. UMB Bank n.a. now owns 2,899 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 1,538 shares during the period. Finally, Park Avenue Securities LLC boosted its stake in shares of Exelixis by 10.6% in the first quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company’s stock valued at $272,000 after purchasing an additional 707 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Stock Up 0.4%

Shares of EXEL stock opened at $41.35 on Friday. The stock has a 50-day simple moving average of $38.68 and a 200 day simple moving average of $39.83. Exelixis, Inc. has a fifty-two week low of $25.17 and a fifty-two week high of $49.62. The stock has a market capitalization of $11.13 billion, a P/E ratio of 19.88, a P/E/G ratio of 0.85 and a beta of 0.38.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business had revenue of $568.26 million during the quarter, compared to analysts’ expectations of $574.36 million. During the same quarter last year, the business posted $0.84 earnings per share. The company’s quarterly revenue was down 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on EXEL shares. Royal Bank Of Canada lowered their price objective on shares of Exelixis from $50.00 to $45.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 29th. UBS Group set a $38.00 price objective on shares of Exelixis and gave the company a “neutral” rating in a research note on Wednesday, July 30th. Guggenheim reaffirmed a “buy” rating and issued a $45.00 target price on shares of Exelixis in a report on Tuesday, July 29th. Morgan Stanley raised their target price on shares of Exelixis from $46.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, September 17th. Finally, HC Wainwright reduced their target price on shares of Exelixis from $53.00 to $46.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $44.42.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.